Parallax Volatility Advisers, L.P. Avadel Pharmaceuticals PLC Call Options Transaction History

Parallax Volatility Advisers, L.P.

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	BUY	$5.02 - $10.0 $501 - $1,000	100 New	100 $0
Q1 2022 May 16, 2022	SELL	$5.46 - $8.29 $238,056 - $361,443	-43,600 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.34 - $11.18 $158,544 - $241,488	21,600 Added 98.18%	43,600 $352,000
Q1 2018 May 15, 2018	BUY	$6.76 - $11.7 $148,720 - $257,399	22,000 New	22,000 $160,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.